FORT LEE, N.J., March 31 /PRNewswire-FirstCall/ -- Alpharma Inc. announced today that Peter G. Tombros has been appointed Chairman of the Board of Directors. Former Chairman, Einar W. Sissener, who acted as Chairman of the Board since 1975, will continue to serve on the company’s board.
“I am extremely pleased with Peter’s appointment as Chairman of the Board,” commented Mr. Sissener. “Peter is the ideal candidate to oversee the board as the company executes its new vision for growth, with over thirty years of broad pharmaceutical experience and twelve years as a member of Alpharma’s board. Alpharma, with its recently streamlined specialty pharmaceutical platform and expanded financial capabilities, is entering a new period in its history.”
Peter G. Tombros has served as a member of Alpharma’s Board of Directors since 1994. He currently is Professor and Distinguished Executive in Residence at the Eberly College of Science, Pennsylvania State University. Mr. Tombros was President and Chief Executive Officer of Enzon, Inc., from 1994 to 2001 and was Chief Executive Officer of Vivoquest, Inc., from 2002 to 2005. He also held senior management positions at Pfizer, Inc for twenty-five years, and currently serves on the Board of Directors of Cambrex Corporation, Dendrite, Inc., NPS Pharmaceuticals, Inc., and Protalex, Inc. Mr. Tombros received Bachelor of Science and Master of Science degrees from Pennsylvania State University, and a Master of Business Administration degree from the University of Pennsylvania Wharton School of Business.
Einar Sissener has been Chairman of Alpharma’s Board of Directors since the company was founded in 1975, and was Chief Executive Officer from 1994 to 1999.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world’s leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Alpharma Inc.
CONTACT: Kathleen Makrakis, VP, Investor Relations of Alpharma Inc.,+1-201-228-5085, kathleen.makrakis@alpharma.com
Web site: http://www.alpharma.com/
